Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers

Overview of attention for article published in Annals of Oncology, September 2025

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 36 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 15,699 followers.

RT @ArndtVogel: Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.